Hepatic basolateral efflux contributes significantly to rosuvastatin disposition I: characterization of basolateral versus biliary clearance using a novel protocol in sandwich-cultured hepatocytes
about
Investigating Transporter-Mediated Drug-Drug Interactions Using a Physiologically Based Pharmacokinetic Model of Rosuvastatin.Identification of hepatic phospholipidosis inducers in sandwich-cultured rat hepatocytes, a physiologically relevant model, reveals altered basolateral uptake and biliary excretion of anionic probe substratesPopulation Pharmacokinetics of Morphine in Patients With Nonalcoholic Steatohepatitis (NASH) and Healthy Adults.Application of a Physiologically Based Pharmacokinetic Model to Predict OATP1B1-Related Variability in Pharmacodynamics of Rosuvastatin.Role of multidrug resistance-associated protein 4 in the basolateral efflux of hepatically derived enalaprilat.Species differences in sinusoidal and canalicular efflux transport of mycophenolic acid 7-O-glucuronide in sandwich-cultured hepatocytes.Pitavastatin is a more sensitive and selective organic anion-transporting polypeptide 1B clinical probe than rosuvastatin.Species differences in hepatobiliary disposition of taurocholic acid in human and rat sandwich-cultured hepatocytes: implications for drug-induced liver injuryAltered morphine glucuronide and bile acid disposition in patients with nonalcoholic steatohepatitisSandwich-Cultured Hepatocytes as a Tool to Study Drug Disposition and Drug-Induced Liver Injury.Hepatic basolateral efflux contributes significantly to rosuvastatin disposition II: characterization of hepatic elimination by basolateral, biliary, and metabolic clearance pathways in rat isolated perfused liver.An experimental approach to evaluate the impact of impaired transport function on hepatobiliary drug disposition using Mrp2-deficient TR- rat sandwich-cultured hepatocytes in combination with Bcrp knockdown.Prediction of pharmacokinetics and drug-drug interactions when hepatic transporters are involved.Hepatic drug transporters: the journey so far.Evaluation of a New Molecular Entity as a Victim of Metabolic Drug-Drug Interactions-an Industry Perspective.Importance of Hepatic Transporters in Clinical Disposition of Drugs and Their Metabolites.Prediction of Altered Bile Acid Disposition Due to Inhibition of Multiple Transporters: An Integrated Approach Using Sandwich-Cultured Hepatocytes, Mechanistic Modeling, and Simulation.Application of the extended clearance concept classification system (ECCCS) to predict the victim drug-drug interaction potential of statins.A Mechanistic Pharmacokinetic Model for Liver Transporter Substrates Under Liver Cirrhosis Conditions.A Clinical Cassette Dosing Study for Evaluating the Contribution of Hepatic OATPs and CYP3A to Drug-Drug Interactions.The involvement of multidrug and toxin extrusion protein 1 in the distribution and excretion of berberine.Inhibition of Intestinal OATP2B1 by the Calcium Receptor Antagonist Ronacaleret Results in a Significant Drug-Drug Interaction by Causing a 2-Fold Decrease in Exposure of Rosuvastatin.Farnesoid X Receptor Agonists Obeticholic Acid and Chenodeoxycholic Acid Increase Bile Acid Efflux in Sandwich-Cultured Human Hepatocytes: Functional Evidence and Mechanisms.Mechanistic Modeling of Pitavastatin Disposition in Sandwich-Cultured Human Hepatocytes: A Proteomics-Informed Bottom-Up Approach.
P2860
Q33581531-B701F1C0-8852-4D1F-B884-B33A0E36CB7DQ33686976-483ECB60-1463-464B-9B5D-1007C9A4EA92Q33729768-C8468087-DAED-4832-993F-F5714E64CEC4Q33994570-A98D9A7F-C398-4618-B5E3-7014AF6EE2CEQ34125053-F9E7ACD4-6EE0-4530-A09D-F62439109AF2Q34286869-FBDF8DA6-08B2-46AB-9061-A62D18DB0277Q34571070-5129FE0E-8D84-488F-8AB9-C610FAAF221CQ35531814-6DA92E95-0FE6-411E-822C-71898B2656AAQ35842935-07D03734-7230-4163-88E8-697284BB7B4BQ36972804-460B62E4-ACF4-421B-A9C6-93B3BD4DE8BAQ37331821-334DDF7C-2A0C-4E6A-9968-AD74D003253FQ37714185-D415E696-8189-4ACE-8916-BA24ED0B631BQ38233298-C364A0BF-AC01-4B6D-99CF-2F428AE20ABEQ38560889-97CD32EB-357D-4B11-886F-7E1CD2D3E21CQ38800092-4D02AD6B-02F6-4A70-A7E5-77DF2094FFA7Q38888365-EF11E583-6D49-498D-822A-30ED73D7E6EDQ39730975-28C500C6-CD4D-450D-8165-433062980030Q40916355-9040E5E8-480B-4663-93FB-AC509D8224C8Q42351660-66FBE4CE-38CB-44C8-BBB6-5DA9DA8D5619Q48172902-38C5EA8B-66FE-42F1-9772-7EBC742383DEQ51098047-9F580717-C296-4902-82C1-5788D41CAA3EQ51396523-B6924C84-147B-469B-A693-A6781140FA57Q52682525-C4BE81C7-5F76-4796-AC68-21974B39930EQ53188214-D06FAFFE-8F85-469F-BE0D-D118A9722E9A
P2860
Hepatic basolateral efflux contributes significantly to rosuvastatin disposition I: characterization of basolateral versus biliary clearance using a novel protocol in sandwich-cultured hepatocytes
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 10 September 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Hepatic basolateral efflux con ...... sandwich-cultured hepatocytes
@en
Hepatic basolateral efflux con ...... sandwich-cultured hepatocytes.
@nl
type
label
Hepatic basolateral efflux con ...... sandwich-cultured hepatocytes
@en
Hepatic basolateral efflux con ...... sandwich-cultured hepatocytes.
@nl
prefLabel
Hepatic basolateral efflux con ...... sandwich-cultured hepatocytes
@en
Hepatic basolateral efflux con ...... sandwich-cultured hepatocytes.
@nl
P2860
P356
P1476
Hepatic basolateral efflux con ...... sandwich-cultured hepatocytes
@en
P2093
Kyunghee Yang
Nathan D Pfeifer
P2860
P304
P356
10.1124/JPET.113.207472
P407
P50
P577
2013-09-10T00:00:00Z